← ANALYST RATINGS · TIPRANKS
Insmed (INSM): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy1 Hold0 Sell
Ratings of 13 analysts in the last 3 months · top analysts only12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $198, the highest $243, the lowest $170. The average is +105.2% from the last price of $96.27.
Analyst ratings 23
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $169 | Buy | +75.5% | Assigned | 13.10.26on TipRanks 06:11 | −1.8%next day +2.1% | ↗ |
| Name not given | — | $192 | Buy | +99.4% | Reiterated | 12.10.26on TipRanks 13:07 | −2.0%next day −1.8% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $220 | Buy | +128.5% | Reiterated | 12.10.26on TipRanks 07:45 | −2.0%next day −1.8% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | — | Hold | — | Downgrade | 12.10.26on TipRanks 05:20 | −2.0%next day −1.8% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $207 | Buy | +115.0% | Reiterated | 11.10.26on TipRanks Oct 12 06:50 | −2.0%next day −1.8% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $218 | Buy | +126.4% | Reiterated | 09.10.26on TipRanks Oct 11 18:55 | −0.5%next day −2.0% · 5 days −2.3% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $195 | Buy | +102.6% | Reiterated | 08.10.26on TipRanks 21:45 | −0.5%next day −2.0% · 5 days −2.3% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $172 | Buy | +78.7% | Reiterated | 07.10.26on TipRanks Oct 8 06:15 | −3.1%next day −0.8% · 5 days −2.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $113 → $117+3.5% | Hold | +21.5% | Reiterated | 05.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $107 → $112+4.7% | Hold | +16.3% | Reiterated | 05.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $111 → $115+3.6% | Hold | +19.5% | Reiterated | 05.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $109 → $114+4.6% | Hold | +18.4% | Reiterated | 05.10.26on TipRanks 16:05 | — | |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $195 | Buy | +102.6% | Reiterated | 05.10.26on TipRanks 11:30 | −7.2%next day +0.8% · 5 days −5.5% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $116 → $119+2.6% | Hold | +23.6% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $110 → $113+2.7% | Hold | +17.4% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $237 → $207−12.7% | Buy | +115.0% | Reiterated | 30.09.26on TipRanks 05:25 | −1.1%next day −5.0% · 5 days −12.8% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $175 | Buy | +81.8% | Reiterated | 28.09.26on TipRanks 07:50 | +0.6%next day −1.5% · 5 days −13.0% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $188 | Buy | +95.3% | Initiated | 24.09.26on TipRanks 04:35 | +2.8%next day −3.6% · 5 days −10.2% | ↗ |
| Adam Walsh★★★★★★★★★★#4262 · hits 43% · avg +4.4% | Roth MKM | $212 → $198−6.6% | Buy | +105.7% | Reiterated | 15.09.26on TipRanks 00:30 | −3.8%next day +2.7% · 5 days −1.6% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $185 → $195+5.4% | Buy | +102.6% | Reiterated | 10.08.26on TipRanks 07:55 | +2.8%next day −1.3% · 5 days −4.7% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $160 → $170+6.2% | Buy | +76.6% | Reiterated | 07.08.26on TipRanks 08:15 | −1.7%next day +2.8% · 5 days −6.0% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $235 | Buy | +144.1% | Reiterated | 06.08.26on TipRanks Aug 7 14:25 | +34.0%next day −1.7% · 5 days −5.9% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $207 → $205−1.0% | Buy | +112.9% | Reiterated | 06.08.26on TipRanks Aug 7 07:45 | +34.0%next day −1.7% · 5 days −5.9% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $243 | Buy | +152.4% | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +34.0%next day −1.7% · 5 days −5.9% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $160 → $175+9.4% | Buy | +81.8% | Reiterated | 06.08.26on TipRanks 14:50 | +34.0%next day −1.7% · 5 days −5.9% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 12:45 | +34.0%next day −1.7% · 5 days −5.9% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $200 | Buy | +107.7% | Reiterated | 17.07.26on TipRanks 08:25 | +1.8%next day −1.0% · 5 days −0.7% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $200 → $185−7.5% | Buy | +92.2% | Reiterated | 08.05.26on TipRanks 09:15 | −4.3%next day +2.3% · 5 days +7.5% | ↗ |
| Qize Ding★★★★★★★★★★#7161 · hits 67% · avg +5.5% | Rothschild & Co Redburn | $263 | Buy | +173.2% | Initiated | 04.12.25on TipRanks 05:30 | −0.9%next day −0.7% · 5 days −5.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Insmed
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 03.10.26: target $198 at a price of $111 (+78.4%); now: $198 at $96.27 (+105.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 25 | 40 | 36 | 32 | 22 |
| Buy | 20 | 12 | 4 | 8 | 9 | 7 |
| Hold | 1 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.39 (from $-0.90 to $-0.09). Last quarter: $-0.06.
Sales
Next quarter’s sales estimate — $497M (from $457M to $515M). Last quarter: $425M.
Best top-analyst consensus in the sector · Healthcare
About Insmed
- CEO: William H. Lewis
- Employees: 1,664
- 700 US Highway 202/206, Bridgewater, NJ, 08807, US
- www.insmed.com
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Data from the stock’s TipRanks forecast page, read 28 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗